ym 529 has been researched along with Bone Diseases, Metabolic in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Akagi, Y; Matushima, S; Ogata, N; Ogata, S; Sudou, T; Sugihara, R; Takao, Y; Toh, U; Watanabe, H | 1 |
| Kinoshita, H; Matsuda, T; Sugi, M; Taniguchi, H; Yanishi, M; Yoshida, T | 1 |
| Fukushima, S; Kimoto, A; Mori, H; Mori, M; Nakamura, T; Nozaki, K; Shiroya, T; Tanaka, M | 1 |
| Fujiwara, D; Imano, M; Itoh, T; Komai, M; Mashimo, K; Mukai, J; Nishida, S; Ogawa, N; Sakaguchi, K; Sakamoto, K; Satou, T; Shimaoka, H; Takeda, T; Tsubaki, M | 1 |
| Kawada, N; Kayasuga, R; Kishikawa, K; Mori, H; Ochi, Y; Tanaka, M; Yamada, H | 1 |
| Inazu, M; Ito, T; Iwata, H; Izumi, R; Kanda, K; Kurokouchi, K; Murata, Y; Ohmori, S; Seo, H; Yasukawa, K | 1 |
1 trial(s) available for ym 529 and Bone Diseases, Metabolic
| Article | Year |
|---|---|
A randomized, open-label, controlled trial of monthly oral minodronate or semiannual subcutaneous injection of denosumab for bone loss by androgen deprivation in Asian men with prostate cancer: the PRevention of Osteopenia with Minodronate And DEnosumab (
Topics: Androgen Antagonists; Androgens; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Denosumab; Diphosphonates; Humans; Imidazoles; Injections, Subcutaneous; Male; Prostatic Neoplasms | 2020 |
5 other study(ies) available for ym 529 and Bone Diseases, Metabolic
| Article | Year |
|---|---|
Efficacy and Safety of Monthly Minodronate Therapy in Postmenopausal Breast Cancer Patients Receiving Aromatase Inhibitors.
Topics: Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Middle Aged; Postmenopause | 2022 |
Intermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatment.
Topics: Animals; Biomarkers; Biomechanical Phenomena; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Diphosphonates; Drug Administration Schedule; Female; Femur; Imidazoles; Lumbar Vertebrae; Organ Size; Ovariectomy; Rats; Rats, Inbred F344; Weight-Bearing | 2013 |
Nitrogen-containing bisphosphonates inhibit RANKL- and M-CSF-induced osteoclast formation through the inhibition of ERK1/2 and Akt activation.
Topics: Alendronate; Animals; Apoptosis; Bone Diseases, Metabolic; Diphosphonates; Humans; Imidazoles; Macrophage Colony-Stimulating Factor; Macrophages; MAP Kinase Signaling System; Mice; Nitrogen; Oncogene Protein v-akt; Osteoclasts; Polyisoprenyl Phosphates; RANK Ligand | 2014 |
Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia.
Topics: Animals; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Bone Remodeling; Diphosphonates; Female; Imidazoles; Osteoporosis; Ovariectomy; Rats; Rats, Inbred F344; Stress, Mechanical | 2008 |
Administration of bisphosphonate prevents disuse bone atrophy induced by tail suspension.
Topics: Animals; Body Weight; Bone Demineralization, Pathologic; Bone Diseases, Metabolic; Bone Resorption; Calcium; Diphosphonates; Femur; Hindlimb Suspension; Humerus; Imidazoles; Male; Phosphorus; Rats; Rats, Wistar; Sodium Chloride; Weightlessness Simulation | 1997 |